S-1 in the treatment of pancreatic cancer

Table 1 Pivotal phase III studies of first-line chemothrapy for advanced pancreatic cancer

Ref.	Treatment	n	ORR	PFS/TTP(mo)	MST(mo)
Burris et al[1]	GEM	63	5.4%	9 wkb	5.65b
	5-FU	63	0%	4 wk	4.41
Moore et al[13]	GEM	284	8%	3.55	5.91
	GEM + erlotinib	285	8.6%	3.75d	6.24e
Conroy et al[14]	GEM	171	9.4%	3.3	6.80
	FOLFIRINOX	171	31.6%d	6.4d	11.1d
Von Hoff et al[15]	GEM	430	7%	3.7	6.70
	GEM + nab-paclitaxel	431	23%d	5.5d	8.50d

^bP < 0.01 vs 5-FU;

^dP < 0.01 vs GEM;

^eP < 0.05 vs GEM. PFS: Progression-free survival; TTP: Time to progression; MST: Median survival time; GEM: Gemcitabine; ORR: Objective response rate; 5-FU: 5-fluorouracil; FOLFIRINOX: Oxaliplatin, irinotecan, fluorouracil and leucovorin.